{
    "Trade/Device Name(s)": [
        "BD Phoenix Automated Microbiology System - Cefuroxime (0.125-4 \u03bcg/mL) EPY",
        "BD Phoenix Automated Microbiology System for use with the antimicrobial agent cefuroxime (0.125-4 \u03bcg/mL) - Streptococcus ID/AST or AST only Phoenix Panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K052270",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020321",
        "K020323",
        "K020322",
        "N50510"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "October 5, 2005",
    "Summary Letter Received Date": "August 19, 2005",
    "Submission Date": "August 17, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Microbiology system"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefuroxime"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates",
        "Aerobic Gram-negative bacteria",
        "Facultative anaerobic Gram-negative bacteria",
        "Gram-positive bacteria (Enterococcus, Streptococcus)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix Automated Microbiology System"
    ],
    "Method(s)/Technology(ies)": [
        "Broth microdilution",
        "Redox indicator growth detection",
        "Automated antimicrobial susceptibility testing"
    ],
    "Methodologies": [
        "Minimal inhibitory concentration (MIC) determination",
        "Automated identification and AST"
    ],
    "Submission Type(s)": [
        "System",
        "Panel",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System with cefuroxime panels for automated antimicrobial susceptibility testing of streptococcal isolates.",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) for Gram-negative and Gram-positive bacterial isolates, including Enterococcus and Streptococcus, using cefuroxime with BD Phoenix Streptococcus ID/AST or AST only panels.",
    "fda_folder": "Microbiology"
}